Epstein–Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics - Scorecard - MDSpire
Advertisement
Epstein–Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics
Clinical Scorecard: Immunosuppression Induced by Epstein–Barr Virus in Nasopharyngeal Carcinoma: An In-Depth Analysis of Viral Mechanisms, Tumor Microenvironment Structure, and Targeted Therapies
At a Glance
Category
Detail
Condition
Nasopharyngeal carcinoma (NPC)
Key Mechanisms
EBV latent proteins and non-coding RNAs activate NF-κB, PI3K/AKT/mTOR, and JAK/STAT pathways, promoting immunosuppression.
Target Population
Patients with nasopharyngeal carcinoma, particularly in regions like Southern China and Southeast Asia.
Care Setting
Oncology clinics and research settings focusing on viral oncology.
Key Highlights
EBV establishes hierarchical immunosuppression in NPC.
Anti-PD-1-based chemo-immunotherapy is the first-line standard for recurrent/metastatic NPC.
Emerging biomarkers include plasma EBV DNA and viral genetic variants for patient stratification.
The tumor microenvironment is conceptualized as five distinct immunosuppressive niches.
Therapeutic strategies targeting EBV dependencies show early promise.
Guideline-Based Recommendations
Diagnosis
Assessment of EBV infection status in NPC patients.
Management
Utilization of anti-PD-1-based therapies for recurrent/metastatic NPC.
Monitoring & Follow-up
Integration of biomarkers such as plasma EBV DNA for monitoring treatment response.
Risks
Potential for differential immune signatures associated with lytic-phase genetic polymorphisms.
Patient & Prescribing Data
Patients with recurrent or metastatic nasopharyngeal carcinoma.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.
